PaulMichaelBarrMD

Hematology • Rochester, NY

Hematologic Oncology

Professor, Medicine, University of Rochester School of Medicine & Dentistry

Join to view full profile

Dr. Barr is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Connect with other colleagues in the same hospital or clinic
Search all U.S. specialist profiles and refer a patient
Read the latest clinical news and earn CME/CEU credits

See Dr. Barr's full profile

Already have an account?

Office
601 Elmwood Ave
Box Med
Rochester, NY 14642
Phone+1 585-275-5823

Fax+1 585-273-1051
Is this information wrong?

Summary

Dr. Paul Barr is a hematologist in Rochester, NY and is affiliated with Strong Memorial Hospital of the University of Rochester. He received his medical degree from Northeast Ohio Medical University and has been in practice 17 years. He specializes in hematologic oncology and is experienced in hematologic oncology, CLL, mantle cell lymphoma, hodgkin's lymphoma, lymphoma, and combined modality therapy. He has more than 100 publications and over 500 citings.

Education & Training

Case Western Reserve University/University Hospitals Cleveland Medical CenterFellowship, Hematology and Medical Oncology, 2004 - 2007
Case Western Reserve University/University Hospitals Cleveland Medical CenterResidency, Internal Medicine, 2000 - 2004
Northeast Ohio Medical UniversityClass of 2000
Miami UniversityB.A., Major: Zoology/Minor: Neuroscience, Magna Cum Laude, 1992 - 1996

Certifications & Licensure

NY State Medical License 2010 - 2026
OH State Medical License 2000 - 2011
American Board of Internal Medicine Hematology
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012
Paul Calabresi Scholar University Hospitals Case Medical Center, Case Western Reserve University, 2008
John W. Harris, MD Hematology Scholar Award 2006
Chief Medical Resident 2003
Department of Zoology Honors Program 1996
Phi Beta Kappa 1996
Howard Hughes Summer Scholars Program 1995
Miami MED Premedical Honorary 1995
Join now to see all

Clinical Trials

Prevalence of Cytomegalovirus, Epstein Barr Virus and Human Herpes 6 Virus in Inflammatory Bowel Disease Start of enrollment: 2005 Apr 01
Completed
Imexon for Relapsed Follicular and Aggressive Lymphomas Start of enrollment: 2011 May 01
Completed
Phase 2
Alisertib in Treating Patients With Relapsed or Refractory Peripheral T-Cell Non-Hodgkin Lymphoma Start of enrollment: 2011 Oct 01
Completed
Phase 2
Efficacy and Safety of Idelalisib in Combination With Bendamustine and Rituximab in Adults With Previously Untreated Chronic Lymphocytic Leukemia Start of enrollment: 2014 Feb 05
Terminated
Phase 3
A Study of Ibrutinib + Obinutuzumab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia Start of enrollment: 2015 Dec 01
Active, not recruiting
Phase 1
An Investigational Immuno-therapy Safety and Effectiveness Study of Nivolumab in Combination With Brentuximab Vedotin to Treat Non-Hodgkin Lymphomas Start of enrollment: 2016 Feb 11
Completed
Phase 1, Phase 2
A Phase 1-2 Dose-Escalation and Cohort-Expansion Study of Oral Tomivosertib (eFT-508) in Subjects With Hematological Malignancies Start of enrollment: 2017 Feb 08
Terminated
Phase 1, Phase 2
Obinutuzumab With or Without Umbralisib, Lenalidomide, or Combination Chemotherapy in Treating Patients With Relapsed or Refractory Grade I-IIIa Follicular Lymphoma Start of enrollment: 2018 Jan 23
Recruiting
Phase 2
A Study Comparing Zanubrutinib With Bendamustine Plus Rituximab in Participants With Previously Untreated CLL or SLL Start of enrollment: 2017 Oct 31
Active, not recruiting
Phase 3
Phase I/II Study of Venetoclax or Lenalidomide in Combination With Ublituximab and Umbralisib in Subjects With Relapsed or Refractory CLL/SLL and NHL Start of enrollment: 2018 Mar 27
Terminated
Phase 1, Phase 2
Assessing Minimal Residual Disease by Next- Generation Sequencing to Minimize Exposure in People With CLL or SLL Who Have Been Treated With Venetoclax Start of enrollment: 2020 May 13
Recruiting
Phase 2
Melanoma Margins Trial-II: 1cm v 2cm Wide Surgical Excision Margins for AJCC Stage II Primary Cutaneous Melanoma Start of enrollment: 2019 Dec 17
Recruiting
Phase 3
Roles: Principal Investigator, Contact
Acalabrutinib and High Frequency Low Dose Subcutaneous Rituximab in Patients With Previously Untreated Chronic Lymphocytic Leukemia / Small Lymphocytic Lymphoma Start of enrollment: 2019 Mar 25
Active, not recruiting
Phase 2
Join now to see all

Publications & Presentations

PubMed

ALK-rearranged CD30-positive poorly differentiated lung adenocarcinoma, mimicking anaplastic large-cell lymphoma.
Giby V George, Danielle S Wallace, Ying Wang, John Carney, Murad Elsadawi, W Richard Burack, Andrew G Evans, Moises J Velez, Siba El Hussein, Barr, P. M., Barr, P. M.,...> ;Histopathology. 2024 Apr 1
Response-adapted, time-limited venetoclax, umbralisib, and ublituximab for relapsed/refractory chronic lymphocytic leukemia.
Hill, B., Ma, S., Zent, C., Baran, A., Wallace, D., Advani, A., Winter, A., Winter, J., Gordan, L., Karmali, R., Liesveld, J., Mulford, D., Rowland, C., Bui, A., Sport...> ;Blood Advances. 2024 Jan 23
Long-term Follow-up from A041202 Shows Continued Efficacy of Ibrutinib Regimens for Older Adults with CLL.
Barr, P. M., Barr, P. M., Barr, P. M., Jennifer A Woyach, Gabriela E Perez Burbano, Amy S Ruppert, Cecelia R Miller, Nyla A Heerema, Weiqiang Zhao, Anna Wall, Wei Ding...> ;Blood. 2024 Jan 12
Integrative analysis of clinicopathological features defines novel prognostic models for mantle cell lymphoma in the immunochemotherapy era: a report from The North Am...
Barr, P. M., Barr, P. M., Julie M Vose, Kai Fu, Lu Wang, Adnan Mansoor, Douglas Stewart, Hongxia Cheng, Lynette Smith, Ji Yuan, Hina Naushad Qureishi, Brian K Link, Me...> ;Journal of Hematology & Oncology. 2023 Dec 16
Outcomes of limited stage primary bone diffuse large B-cell lymphoma in the rituximab era: a multicenter, retrospective study.
Barr, P. M., Barr, P. M., Barr, P. M., Karmali, R., Alexandra Rezazadeh, Aniko Szabo, Arushi Khurana, David J Inwards, Matthew A Lunning, Nancy L Bartlett, Paolo F Cai...> ;Haematologica. 2023 Oct 19
1 citations
Nivolumab combined with brentuximab vedotin for R/R primary mediastinal large B-cell lymphoma: a 3-year follow-up.
Pier Luigi Zinzani, Armando Santoro, Giuseppe Gritti, Pauline Brice, Paul M Barr, John Kuruvilla, David Cunningham, Justin Kline, Nathalie A Johnson, Neha Mehta-Shah, ...> ;Blood Advances. 2023 Sep 26
5 citations
Outcomes in Patients with High-Risk Features after Fixed-Duration Ibrutinib plus Venetoclax: Phase II CAPTIVATE Study in First-Line Chronic Lymphocytic Leukemia.
Barr, P. M., Barr, P. M., John N Allan, Ian W Flinn, Tanya Siddiqi, Paolo Ghia, Constantine S Tam, Thomas J Kipps, Paul M Barr, Anna Elinder Camburn, Alessandra Tedesc...> ;Clinical Cancer Research. 2023 Jul 14
Phase 2 trial of umbralisib, ublituximab, and venetoclax in patients with relapsed/refractory mantle cell lymphoma.
Danielle S Wallace, Chris Rowland, Brian T Hill, Andrea M Baran, Carla Casulo, Patrick M Reagan, Allison Winter, Reem Karmali, Jane N Winter, Leo I Gordon, Andrew Bui,...> ;Leukemia & Lymphoma. 2023 Sep 1
2 citations
Healthcare Utilization Disparities of Adolescent and Young Adults Compared to the Older Lymphoma Population.
Kriti Thapa, Myla Strawderman, Patrick M Reagan, Paul M Barr, Clive S Zent, Jonathan W Friedberg, Tina Faugh, Carla Casulo> ;Clinical Lymphoma, Myeloma & Leukemia. 2023 Sep 1
1 citations
Rituximab induced cytokine release with high serum IP-10 (CXCL10) concentrations is associated with infusion reactions.
Jeremiah E Moore, Paige C Bloom, Charles C Chu, Jennifer E Bruno, Christine A Herne, Andrea M Baran, Sally A Quataert, Timothy R Mosmann, Ronald P Taylor, Danielle S W...> ;Leukemia Research. 2023 Jun 1
3 citations
Treatment Discontinuation Patterns for Patients With Chronic Lymphocytic Leukemia in Real-World Settings: Results From a Multi-Center International Study.
Mazyar Shadman, Beenish S Manzoor, Kavita Sail, Hande H Tuncer, John N Allan, Chaitra Ujjani, Nnadozie Emechebe, Rajesh Kamalakar, Catherine C Coombs, Lori Leslie, Pau...> ;Clinical Lymphoma, Myeloma & Leukemia. 2023 Jul 1
1 citations
A phase 1b study of ibrutinib in combination with obinutuzumab in patients with relapsed or refractory chronic lymphocytic leukemia.
Christine E Ryan, Danielle M Brander, Paul M Barr, Svitlana Tyekucheva, Liam R Hackett, Mary C Collins, Stacey M Fernandes, Yue Ren, Yinglu Zhou, Mikaela M McDonough, ...> ;Leukemia. 2023 Apr 1
4 citations
Acalabrutinib and high-frequency low-dose subcutaneous rituximab for initial therapy of chronic lymphocytic leukemia.
Danielle S Wallace, Clive S Zent, Andrea M Baran, Patrick M Reagan, Carla Casulo, Geoffrey Rice, Jonathan W Friedberg, Paul M Barr> ;Blood Advances. 2023 Jun 13
1 citations
Characteristics and Clinical Outcomes of Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Receiving Ibrutinib for ≥5 Years in the RESONATE-2 Study.
Jennifer A Woyach, Paul M Barr, Thomas J Kipps, Jacqueline C Barrientos, Inhye E Ahn, Paolo Ghia, Vincent Girardi, Emily Hsu, Mandy Jermain, Jan A Burger> ;Cancers. 2023 Jan 13
4 citations
Relevance of Bone Marrow Biopsies for Response Assessment in US National Cancer Institute National Clinical Trials Network Follicular Lymphoma Clinical Trials.
Rutherford, S., Yin, J., Pederson, L., Perez Burbano, G., LaPlant, B., Shadman, M., Li, H., LeBlanc, M., Kenkre, V., Hong, F., Blum, K., Dockter, T., Martin, P., Jung,...> ;Journal of Clinical Oncology. 2023 Jan 10
Many People With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Benefit From Ibrutinib Treatment Up To 8 Years: A Plain Language Summary.
Paul M Barr, Carolyn Owen, Tadeusz Robak, Alessandra Tedeschi, Osnat Bairey, Jan A Burger, Peter Hillmen, Claire Dearden, Sebastian Grosicki, Helen McCarthy, Jian Yong...> ;Future Oncology. 2023 Jan 9
1 citations
Effective Tumor Debulking with Ibrutinib Before Initiation of Venetoclax: Results from the CAPTIVATE Minimal Residual Disease and Fixed-Duration Cohorts.
Paul M Barr, Alessandra Tedeschi, William G Wierda, John N Allan, Paolo Ghia, Daniele Vallisa, Ryan Jacobs, Susan O'Brien, Andrew P Grigg, Patricia Walker, Cathy Zhou,...> ;Clinical Cancer Research. 2022 Oct 14
19 citations
Venetoclax retreatment of patients with chronic lymphocytic leukemia after a previous venetoclax-based regimen.
Meghan C Thompson, Rosemary A Harrup, Catherine C Coombs, Lindsey E Roeker, Jeffrey J Pu, Michael Y Choi, Paul M Barr, John N Allan, Martin Šimkovič, Lori Leslie, Joan...> ;Blood Advances. 2022 Aug 9
83 citations
Long-term outcomes for ibrutinib-rituximab and chemoimmunotherapy in CLL: updated results of the E1912 trial.
Tait D Shanafelt, Xin Victoria Wang, Curtis A Hanson, Elisabeth M Paietta, Susan O'Brien, Jacqueline Barrientos, Diane F Jelinek, Esteban Braggio, Jose F Leis, Cong Ch...> ;Blood. 2022 Jul 14
3 citations
Phase 1/2 study of acalabrutinib and the PI3K delta inhibitor ACP-319 in relapsed/refractory B-cell Non-Hodgkin lymphoma.
Paul M Barr, Stephen D Smith, Mark J Roschewski, Susan M O'Brien, Jeff P Sharman, Jason M Melear, Priti Patel, Roser Calvo, Helen Yang, Stephen E Spurgeon> ;Leukemia & Lymphoma. 2022 Jul 1
Characterization of low-grade arthralgia, myalgia, and musculoskeletal pain with ibrutinib therapy: pooled analysis of clinical trials in patients with chronic lymphoc...
Tanya Siddiqi, Steven Coutre, Matthew McKinney, Paul M Barr, Kerry Rogers, Ahmad Mokatrin, Rudy Valentino, Anita Szoke, Sanjay Deshpande, Angeline Zhu, Israel Arango-H...> ;Leukemia & Lymphoma. 2022 Jul 1
87 citations
Up to 8-year follow-up from RESONATE-2: first-line ibrutinib treatment for patients with chronic lymphocytic leukemia.
Paul M Barr, Carolyn Owen, Tadeusz Robak, Alessandra Tedeschi, Osnat Bairey, Jan A Burger, Peter Hillmen, Steve E Coutre, Claire Dearden, Sebastian Grosicki, Helen McC...> ;Blood Advances. 2022 Jun 14
67 citations
Fixed-duration ibrutinib plus venetoclax for first-line treatment of CLL: primary analysis of the CAPTIVATE FD cohort.
Constantine S Tam, John N Allan, Tanya Siddiqi, Thomas J Kipps, Ryan Jacobs, Stephen Opat, Paul M Barr, Alessandra Tedeschi, Livio Trentin, Rajat Bannerji, Sharon Jack...> ;Blood. 2022 Jun 2
2 citations
The highly selective Bruton tyrosine kinase inhibitor acalabrutinib leaves macrophage phagocytosis intact.
Jonathan J Pinney, Sara K Blick-Nitko, Andrea M Baran, Derick R Peterson, Hannah E Whitehead, Raquel Izumi, Veerendra Munugalavadla, Karl R Van DerMeid, Paul M Barr, C...> ;Haematologica. 2022 Jun 1
23 citations
Zilovertamab Vedotin Targeting of ROR1 as Therapy for Lymphoid Cancers.
Barr, P. M., Barr, P. M., Michael L Wang, Jacqueline C Barrientos, Richard R Furman, Matthew Mei, Paul M Barr, Michael Y Choi, Sven de Vos, Avyakta Kallam, Krish Patel...> ;NEJM Evidence. 2022 Jan 1
Join now to see all

Journal Articles

Sustained Efficacy and Detailed Clinical Follow-up of First-Line Ibrutinib Treatment in Older Patients with Chronic Lymphocytic Leukemia: Extended Phase 3 Results from...
Steven Coutre, Thomas J Kipps, Jan A Burger, Nancy L Bartlett, Paul M Barr, Haematologica
Recommendations for Clinical Trial Development in Follicular Lymphoma
Maddocks K, Barr PM, Cheson BD, Little RF, Baizer L, Kahl BS, Leonard JP, Fowler N, Gordon LI, Link BK, Friedberg JW, Ansell SM, J Natl Cancer Inst, 1/31/2016
Prospective Clinicogenetic Risk Models To Predict Early Progression of Follicular Lymphoma after First-Line Immunochemotherapy
Jurinovic V; Kridel R; Staiger AM; Szczepanowski M; Horn H; Dreyling MH; Rosenwald A; Ott G; Klapper W; Zelenetz AD; Barr PM; Friedberg JW; Ansell S; Sehn LH; Connors ..., Blood, 1/25/2016
"US Intergroup Trial of Response-Adapted Therapy for Stage III to IV Hodgkin Lymphoma Using Early Interim Fluorodeoxyglucose-Positron Emission Tomography Imaging: Sout...
Press OW; Li H; Schoder H; Straus DJ; Moskowitz CH; LeBlanc M; Rimsza LM; Bartlett NL; Evens AM; Mittra ES; LaCasce AS; Sweetenham JW; Barr PM; Fanale MA; Knopp MV; No..., Journal of Clinical Oncology, 1/10/2016
Deregulation of NF-kB, ie, a useful PMBL marker
Barr PM, Blood, 1/1/2016
Phase 1 Trial of Carfilzomib (PR-171) in Combination with Vorinostat (SAHA) in Patients with Relapsed or Refractory B-Cell Lymphomas
Holkova B, Kmieciak M, Bose P, Yazbeck VY, Barr PM, Tombes MB, Shrader E, Weir-Wiggins C, Rollins AD, Cebula EM, Pierce E, Herr M, Sankala H, Hogan KT, Wan W, FengC , ..., Leukemia and Lymphoma, 1/1/2016
Post-ibrutinib outcomes in patients with mantle cell lymphoma
Martin P, Maddocks K, Leonard JP, Ruan J, Goy A, Wagner-Johnston N, Rule S, Advani R, Iberri D, Phillips T, Spurgeon S, Kozin E, Noto K, Chen Z, Jurczak W, Auer R, Chm..., Blood, 1/1/2016
"Phase 2 study of idelalisib and entospletinib: pneumonitis limits combination therapy in relapsed refractory CLL and NHL"
Barr PM; Saylors GB; Spurgeon SE; Cheson BD; Greenwald DR; O'Brien SM; Liem AK; McIntyre RE; Joshi A; Abella-Dominicis E; Hawkins MJ; Reddy A; Di Paolo J; Lee H; He J;..., Blood, 1/1/2016
"Phase 1 study of single-agent CC-292, a highly selective Bruton's tyrosine kinase inhibitor, in relapsed or refractory chronic lymphocytic leukemia"
Brown JR; Harb WA; Hill BT; Gabrilove J; Sharman JP; Schreeder MT; Barr PM; Foran JM; Miller TP; Burger JA; Kelly KR; Mahadevan D; Ma S; Li Y; Pierce DW; Barnett E; Ma..., Haematologica, 1/1/2016
Survival of Secondary Central Nervous System Lymphoma Patients in the Rituximab Era
Herr MM; Mohile NA; Barr PM; van Wijngaarden E; Brown EB; Rich DQ, Clinical Lymphoma, Myeloma & Leukemia, 1/1/2016
"Outcomes of CLL patients treated with sequential kinase inhibitor therapy: a real world experience"
Mato AR; Nabhan C; Barr PM; Ujjani CS; Hill BT; Lamanna N; Skarbnik AP; Howlett C; Pu JJ; Sehgal AR; Strelec LE; Vandegrift A; Fitzpatrick DM; Zent CS; Feldman T; Goy ..., Blood, 1/1/2016
Prognostic Impact of Cell of Origin in Limited-Stage Diffuse Large B-Cell Lymphoma Treated With R-CHOP With or Without Radiation Therapy
Youn P; Cummings MA; Dhakal S; Burack WR; Casulo C; Barr PM; Friedberg JW; Constine LS, International Journal of Radiation Oncology, Biology, Physics, 1/1/2016
Phase II intergroup trial of alisertib in relapsed and refractory peripheral T-cell lymphoma and transformed mycosis fungoides: SWOG 1108
Barr PM, Li H, Spier C, Mahadevan D, LeBlanc M, Ul Haq M, Huber BD, Flowers CR, Wagner-Johnston ND, Horwitz SM, Fisher RI, Cheson BD, Smith SM, Kahl BS, Bartlett NL, F..., Journal of Clinical Oncology, 1/20/2015
"Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia"
Burger JA, Tedeschi A, Barr PM, Robak T, Owen C, Ghia P, Bairey O, Hillmen P, Bartlett NL, Li J, Simpson D, Grosicki S, Devereux S, McCarthy H, Coutre S, Quach H, Gaid..., The New England Journal of Medicine, 1/17/2015
The Bruton's tyrosine kinase inhibitor, ibrutinib, with chemoimmunotherapy in patients with chronic lymphocytic leukemia
Brown JR, Barrientos JC, Barr PM, Flinn IW, Burger JA, Tran A, Clow F, James DF, Graef T, Friedberg JF, Rai K, O'Brien S, Blood, 1/7/2015
Rituximab maintenance in follicular lymphoma
Barr PM, Clinical Advances In Hematology & Oncology, 1/1/2015
Targeting B Cell Receptor Signaling with Ibrutinib in Diffuse Large B Cell Lymphoma
Wilson WH, Young RM, Schmitz R, Yang Y, Pittaluga S, Wright G, Lih CJ, Williams PM, Shaffer AL, Gerecitano J, de Vos S, Goy A, Kenkre VP, Barr PM, Blum KA, Shustov A, ..., Nature Medicine, 1/1/2015
Recent advances in the development of Aurora kinase inhibitors in hematological malignancies
Choudary I, Barr PM, Friedberg J, Therapeutic Advances in Hematology, 1/1/2015
Attempting to avoid chemotherapy in CLL with lenalidomide and rituximab
Barr PM, Journal of Clinical Oncology, 1/27/2014
Infection in chronic lymphocytic leukemia: parsimony has its limits
Barr PM, Zent CS, Leukemia & Lymphoma, 1/25/2014
Ibrutinib versus Ofatumumab in Previously Treated Chronic Lymphoid Leukemia
Byrd JC, Brown JR, O'Brien S, Barrientos JC, Kay NE, Reddy NM, Coutre S, Tam CS, Mulligan SP, Jaeger U, Devereux S, Barr PM, Furman RR, Kipps TJ, Cymbalista F, Pocock ..., The New England Journal of Medicine, 1/17/2014
Impact of dietary supplements, obesity, and treatment initiation on serum vitamin D levels in lymphoma patients
Hutchinson K, Jahangiri S, Calvi LM, Barr PM, Friedberg JW, Kelly JL, Leukemia & Lymphoma, 1/15/2014
The ABC of CLL: Etiology of Cytopenias is Important in Staging and Management
Barr PM, Zent CS, Leukemia & Lymphoma, 1/1/2014
Maintenance rituximab should be considered for patients with follicular lymphoma
Barr PM, Clinical Advances In Hematology & Oncology, 1/1/2014
Crizotinib as Salvage and Maintenance with Allogeneic Stem Cell Transplantation for Refractory Anaplastic Large Cell Lymphoma
Cleary JM, Rodig S, Barr PM, Shinagare AB, Clark J, Shaprio GI, Armand P, Journal of the National Comprehensive Cancer Network, 1/1/2014
Join now to see all

Books/Book Chapters

Rare Lymphomas
Chapter: Adult Burkitt Lymphoma and Leukemia.
Page 171 - 194Gokbuget N, Barr PM, Friedberg JW, Hsi ED, Ott GEditors: Dreyling M.Springer-Verlag Berlin Heidelberg, New York2014
Textbook of Uncommon Cancers
Chapter: Rare B Cell Lymphoproliferative Disorders.
Barr PM, Friedberg JWEditors: Sekkeres MA.Wiley-Blackwell, Oxford, EnglandEdition 4th,2012
Adult Acute Lymphocytic Leukemia: Biology and Treatment
Chapter: Pharmacology of Acute Lymphoblastic Leukemia Therapy.
Barr PM, Creger RJ, Berger NAEditors: Advani A, Lazarus HM.Humana Press, New York, NY2010
Cancer, Principles & Practice of Oncology
Chapter: Non-Hodgkin lymphomas.
Barr PMEditors: Devita VT, Lawrence TS, Rosenberg SA.Lippincott Williams & WilkinsEdition 9th,2008
Join now to see all

Abstracts/Posters

Anti-CD20 Therapy Reliance on Antibody-Dependent Cellular Phagocytosis Affects Combination Drug Choice
Paul M. Barr, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Treatment Discontinuation Patterns for Patients with CLL in the Real-World Settings: Results from a Multi-Center Study
Paul M. Barr, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Using Ibrutinib in Earlier Lines of Treatment Results in Better Outcomes for Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Paul M. Barr, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Utilization and Early Discontinuation of First-Line Ibrutinib for Patients with Chronic Lymphocytic Leukemia Treated in the Community Oncology Setting in the United St...
Paul M. Barr, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Ibrutinib and Rituximab Provides Superior Clinical Outcome Compared to FCR in Younger Patients with Chronic Lymphocytic Leukemia (CLL): Extended Follow-up from the E19...
Paul M. Barr, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Efficacy of Therapies Following Venetoclax Discontinuation in CLL: Focus on B-Cell Receptor Signal Transduction Inhibitors and Cellular Therapies
Paul M. Barr, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Treatment Sequences and Outcomes of Patients with CLL Treated with Venetoclax and Other Novel Agents Post Introduction of Novel Therapies
Paul M. Barr, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
A Pilot Study of Brentuximab Vedotin Combined with AVD Chemotherapy and Radiotherapy in Patients with Newly Diagnosed Early Stage, Unfavorable Risk Hodgkin Lymphoma
Paul M. Barr, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Treatment Sequences and Outcomes of Patients with CLL Treated with Venetoclax and Other Novel Agents Post Introduction of Novel Therapies
Paul M. Barr, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Ibrutinib (Ibr) Plus Venetoclax (Ven) for First-Line Treatment of Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL): Results from the MRD Cohort of t...
Paul M. Barr, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
PET-Directed Therapy for Patients with Limited-Stage Diffuse Large B-Cell Lymphoma - Results of Intergroup Nctn Study S1001
Paul M. Barr, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
"Phase II Study of RCHOP, Consolidative RIT and Maintenance Rituximab: 5-year results of S0801"
Barr PM, American Society of Hematology Annual Meeting, San Diego, CA, 1/5/2016
"Updated Efficacy and Safety from the Phase 3 RESONATE-2™ Study: Ibrutinib as First-Line Treatment Option in Patients 65 Years and Older With Chronic Lymphocytic Leuke...
Barr PM, American Society of Hematology Annual Meeting, San Diego, CA, 1/3/2016
Join now to see all

Lectures

Final analysis from RESONATE: Six-year follow-up in patients (pts) with previously treated chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) on ibru...
2019 ASCO Annual Meeting - 6/1/2019
Nivolumab Combined with Brentuximab Vedotin for Relapsed/Refractory Primary Mediastinal Large B-Cell Lymphoma: Preliminary Results from the Phase 2 CheckMate 436 Trial
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Five-Year Outcomes of SWOG S0: A Randomized Phase II US Intergroup Study of R-HCVAD Vs. R-Bendamustine Followed By Autologous Stem Cell Transplant for Patients with Ma...
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Acalabrutinib combined with PI3K inhibitor ACP-319 in patients (pts) with relapsed/refractory (R/R) B-cell malignancies.
2018 ASCO Annual Meeting - Chicago, Illinois - 06/4/2018
"Indolent non-Hodgkin lymphoma"
Cleveland, OH - 1/21/2016
"Surviving FDA inspections"
Chicago, IL - 1/21/2016
"Changing Clinical Trial Designs"
1/18/2016
"Future Applications of Idelalisib"
Whistler, British Columbia, Canada - 1/3/2016
"Lymphoma Overview"
Rochester, NY - 1/2/2016
"Optimal Management of Deletion 17p CLL: Novel Agents"
New York, NY - 1/1/2016
"Abbvie CLL day-Current diagnosis and management of CLL"
1/26/2015
"Chronic Lymphocytic Leukemia"
San Diego, CA - 1/23/2015
"Changing Treatment Paradigms in Lymphoma and CLL-2014 ASH update"
Rochester, NY - 1/18/2015
"PI3K and Syk Inhibition Limited by Pneumonitis; Results of a Phase II Trial"
Lugano, Switzerland - 1/16/2015
"Building on B-cell receptor signaling in chronic lymphocytic leukemia"
Rochester, NY - 1/12/2015
"Lymphoma Education and Advocacy Partners Webinar-Advocacy for Lymphoma Clinical Trials"
1/2/2015
"Syk inhibition in CLL"
Whistler, British Columbia, Canada - 1/27/2014
"Targeting Aurora Kinase in Peripheral T cell Lymphoma"
San Francisco, CA - 1/25/2014
"Return on Investments in Clinical Research"
Chicago, IL - 1/10/2014
"Protein Kinase Inhibition in Peripheral T-cell Lymphoma"
San Francisco, CA - 1/6/2014
"Special Considerations for TP53 Dysfunction in CLL"
New York, NY - 1/1/2014
"CLL; Management in the current era"
Rochester, NY - 1/30/2013
"Diffuse large B cell lymphoma; Current Research Initiatives"
Cornell Veterinary School, Ithaca, NY - 1/20/2013
"Research and Clinical Trials"
University of Rochester, Rochester, NY - 1/14/2013
"Changing Paradigms in Hematologic Malignancies"
University of Rochester - 1/13/2013
Join now to see all

Other

Clinical evaluation and management of Burkitt Lymphoma
Barr PM, Friedberg JW, Clinical Decision Support in Hematology, 1st Edition
1/1/2013
Non-Hodgkin Lymphoma.
Barr PM and Fisher RI, Clinical Care Options in Practice (Govindan R, Kantarjian H.(eds)
1/1/2009

Press Mentions

Results from IMBRUVICA® (Ibrutinib) RESONATE-2 Study Provide up to Seven Years of Progression-Free and Overall Survival Data in First-Line Chronic Lymphocytic Leukemia (CLL)June 4th, 2021
Long-Term Follow-up Supports Early Use of Ibrutinib in CLLDecember 9th, 2019
Is Maintenance Therapy with Rituximab for Follicular Lymphoma a Good Idea?December 13th, 2016
Join now to see all